Literature DB >> 29247298

Worsening of soft tissue dystrophic calcification in an osteoporotic patient treated with teriparatide.

T D Htet1,2, J A Eisman3,4,5, G J Elder3,4,6, J R Center3,4,5.   

Abstract

Teriparatide, used for treatment of osteoporosis in patients at high risk of fracture risk, sometimes results in mild and transient hypercalcemia. There have been two recent reports of worsening dystrophic calcification in patients with autoimmune disorders following teriparatide treatment. We report a patient with severe osteoporosis and without a pre-existing autoimmune disorder, who developed symptomatic worsening of dystrophic calcification 4 months after teriparatide was initiated. Symptoms resolved within 1 week of teriparatide cessation.

Entities:  

Keywords:  Dystrophic calcification; Osteoporosis; Teriparatide

Mesh：

Substances：

Year:  2017        PMID： 29247298     DOI： 10.1007/s00198-017-4330-7

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


  10 in total

Review 1.  The cellular and clinical parameters of anabolic therapy for osteoporosis.

Authors:  Clifford J Rosen
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2003       Impact factor: 1.807

Review 2.  Cutaneous deposition diseases. Part II.

Authors:  D M Touart; P Sau
Journal:  J Am Acad Dermatol       Date:  1998-10       Impact factor: 11.527

3.  Cutaneous vascular calcifications secondary to treatment with teriparatide.

Authors:  V M Leis-Dosil; C Rubio-Flores; E Ruiz-Bravo Burguillos; R M Díaz-Díaz
Journal:  Actas Dermosifiliogr       Date:  2012-07-26

Review 4.  Calcinosis cutis: part I. Diagnostic pathway.

Authors:  Nadine Reiter; Laila El-Shabrawi; Bernd Leinweber; Andrea Berghold; Elisabeth Aberer
Journal:  J Am Acad Dermatol       Date:  2011-07       Impact factor: 11.527

5.  Nonuremic calciphylaxis in a patient with rheumatoid arthritis and osteoporosis treated with teriparatide.

Authors:  Arturo R Dominguez; Shauna E Goldman
Journal:  J Am Acad Dermatol       Date:  2014-02       Impact factor: 11.527

6.  Worsening of calcinosis cutis with teriparatide treatment in two osteoporotic patients.

Authors:  A F Echeverri; F E Ospina; C A Cañas; A Agualimpia; J P Suso; G J Tobón; F Bonilla-Abadía
Journal:  Br J Dermatol       Date:  2016-06-20       Impact factor: 9.302

Review 7.  Calcinosis in rheumatic diseases.

Authors:  Nina Boulman; Gleb Slobodin; Michael Rozenbaum; Itzhak Rosner
Journal:  Semin Arthritis Rheum       Date:  2005-06       Impact factor: 5.532

8.  Nonuremic calciphylaxis precipitated by teriparatide [rhPTH(1-34)] therapy in the setting of chronic warfarin and glucocorticoid treatment.

Authors:  E K Spanakis; D E Sellmeyer
Journal:  Osteoporos Int       Date:  2013-11-29       Impact factor: 4.507

9.  The expression of molecular mediators in the idiopathic cutaneous calcification and ossification.

Authors:  So Young Kim; Hae Young Choi; Ki Bum Myung; You Won Choi
Journal:  J Cutan Pathol       Date:  2008-04-18       Impact factor: 1.587

10.  A case report of severe calciphylaxis - suggested approach for diagnosis and treatment.

Authors:  Margret Patecki; Gabriele Lehmann; Jan Hinrich Bräsen; Jessica Schmitz; Anna Bertram; Lars Daniel Berthold; Hermann Haller; Wilfried Gwinner
Journal:  BMC Nephrol       Date:  2017-04-21       Impact factor: 2.388
  10 in total
  1 in total

1.  Calcified Diverticula in the Setting of Per Rectal Bleed.

Authors:  Sindhura Kolli; Vahe Shahnazarian; Madhavi Reddy
Journal:  Cureus       Date:  2018-08-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.